Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors
摘要:
Structure-guided de novo drug design led to the identification of a novel series of substituted pyridine derivatives as HIF-1 alpha prolyl hydroxylase inhibitors. Pyridine carboxyamide derivatives bearing a substituted aryl group at the 5-position of the pyridine ring show appreciable activity, while constraining the side chain by placing a pyrazole carboxylic acid generated a potent lead series with consistent activity against EGLN-1. (c) 2006 Elsevier Ltd. All rights reserved.
Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors
作者:Namal C. Warshakoon、Shengde Wu、Angelique Boyer、Richard Kawamoto、Justin Sheville、Ritu Tiku Bhatt、Sean Renock、Kevin Xu、Matthew Pokross、Songtao Zhou、Richard Walter、Marlene Mekel、Artem G. Evdokimov、Stephen East
DOI:10.1016/j.bmcl.2006.08.026
日期:2006.11
Structure-guided de novo drug design led to the identification of a novel series of substituted pyridine derivatives as HIF-1 alpha prolyl hydroxylase inhibitors. Pyridine carboxyamide derivatives bearing a substituted aryl group at the 5-position of the pyridine ring show appreciable activity, while constraining the side chain by placing a pyrazole carboxylic acid generated a potent lead series with consistent activity against EGLN-1. (c) 2006 Elsevier Ltd. All rights reserved.
INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
申请人:[en]ACCENT THERAPEUTICS, INC.
公开号:WO2023154519A1
公开(公告)日:2023-08-17
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.